ArticleJHLT open2024
Leveraging blood-based transcriptomics to detect acute cellular rejection in lung transplant.
Article in JHLT open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex-related transcriptomic differences in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026Article
- LungGENIE: the lung gene-expression and network imputation engine.BMC genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute cellular rejection (ACR) is one of the main risk factors for chronic allograft dysfunction, the primary contributor to poor long-term survival in lung transplant recipients. We sought to develop a blood-based transcriptomic risk score (TRS) to detect ACR in lung transplant recipients. We tested for the association of the TRS with ACR in a logistic mixed model. We analyzed 101 samples from 75 individuals. We identified 4 genes after application of the least absolute shrinkage and selection operator. The TRS was significantly associated with ACR (odds ratio (OR) 3.43, 95% confidence interval (CI) 1.86-7.14,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.